Search

Your search keyword '"Fernández-Morales A"' showing total 18 results
Start Over Author "Fernández-Morales A" Journal annals of oncology
18 results on '"Fernández-Morales A"'

1. 848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801

Author

Marquez-Rodas, I., primary, Berciano Guerrero, M.A., additional, Muñoz Couselo, E., additional, Soria, A., additional, Cerezuela-Fuentes, P., additional, Manzano Mozo, J.L., additional, Gutierrez Sanz, L., additional, Crespo, G., additional, Puértolas, T., additional, Garcia Castano, A., additional, Aguado de la Rosa, C., additional, Espinosa, E., additional, Majem Tarruella, M., additional, López Castro, R., additional, Ayala de Miguel, P., additional, Medina Martinez, J., additional, Fernández Morales, L.A., additional, Bellido Hernández, L., additional, Berrocal, A., additional, and Martín Algarra, S., additional

Published
2022
Full Text
View/download PDF

2. 802P Demography and clinical outcomes of adjuvant therapy in Spain: Results from GEM 1801 study

Author

Martín Algarra, S., primary, Piñero Madrona, A., additional, Berciano-Guerrero, M-Á., additional, Muñoz Couselo, E., additional, Soria, A., additional, Manzano, J.L., additional, Gutiérrez Sanz, L., additional, Crespo, G., additional, Puértolas, T., additional, García Castaño, A., additional, Aguado de la Rosa, C., additional, Espinosa, E., additional, Majem, M., additional, López Castro, R., additional, Ayala de Miguel, P., additional, Medina Martínez, J., additional, Fernández-Morales, L.A., additional, Bellido, L., additional, Cerezuela-Fuentes, P., additional, and Márquez-Rodas, I., additional

Published
2022
Full Text
View/download PDF

3. 863P Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801

Author

Muñoz Couselo, E., primary, Ortiz Vélez, C., additional, Berciano-Guerrero, M-Á., additional, Soria, A., additional, Cerezuela-Fuentes, P., additional, Manzano, J.L., additional, Gutiérrez Sanz, L., additional, Crespo, G., additional, Puértolas, T., additional, García Castaño, A., additional, Aguado de la Rosa, C., additional, Espinosa, E., additional, Majem, M., additional, López Castro, R., additional, Ayala de Miguel, P., additional, Medina Martínez, J., additional, Fernández-Morales, L.A., additional, Bellido, L., additional, Martín Algarra, S., additional, and Márquez-Rodas, I., additional

Published
2022
Full Text
View/download PDF

4. 811P Three-years real-world evidence of adjuvant dabrafenib plus trametinib (DT) in patients with resected melanoma in Spain (GEM 1901 - DESCRIBE-AD)

Author

Cerezuela-Fuentes, P., primary, Martín-Liberal, J., additional, Fernández-Morales, L.A., additional, Benítez, G., additional, Medina Martinez, J., additional, Quindós, M., additional, García Castaño, A., additional, Puértolas, T., additional, Vilchez Simo, R., additional, Fernández, O., additional, Majem, M., additional, Bellido Hernández, L., additional, Ayala de Miguel, P., additional, Campos, B., additional, Espinosa, E., additional, Macías Cerrolaza, J.A., additional, Rodríguez-Lescure, A., additional, Espasa Font, L., additional, Belaustegui Ferrández, G., additional, and Manzano Mozo, J.L., additional

Published
2022
Full Text
View/download PDF

5. 848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801

Author

I. Marquez-Rodas, M.A. Berciano Guerrero, E. Muñoz Couselo, A. Soria, P. Cerezuela-Fuentes, J.L. Manzano Mozo, L. Gutierrez Sanz, G. Crespo, T. Puértolas, A. Garcia Castano, C. Aguado de la Rosa, E. Espinosa, M. Majem Tarruella, R. López Castro, P. Ayala de Miguel, J. Medina Martinez, L.A. Fernández Morales, L. Bellido Hernández, A. Berrocal, and S. Martín Algarra

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

6. 811P Three-years real-world evidence of adjuvant dabrafenib plus trametinib (DT) in patients with resected melanoma in Spain (GEM 1901 - DESCRIBE-AD)

Author

P. Cerezuela-Fuentes, J. Martín-Liberal, L.A. Fernández-Morales, G. Benítez, J. Medina Martinez, M. Quindós, A. García Castaño, T. Puértolas, R. Vilchez Simo, O. Fernández, M. Majem, L. Bellido Hernández, P. Ayala de Miguel, B. Campos, E. Espinosa, J.A. Macías Cerrolaza, A. Rodríguez-Lescure, L. Espasa Font, G. Belaustegui Ferrández, and J.L. Manzano Mozo

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

7. 863P Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801

Author

E. Muñoz Couselo, C. Ortiz Vélez, M-Á. Berciano-Guerrero, A. Soria, P. Cerezuela-Fuentes, J.L. Manzano, L. Gutiérrez Sanz, G. Crespo, T. Puértolas, A. García Castaño, C. Aguado de la Rosa, E. Espinosa, M. Majem, R. López Castro, P. Ayala de Miguel, J. Medina Martínez, L.A. Fernández-Morales, L. Bellido, S. Martín Algarra, and I. Márquez-Rodas

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

8. 1174P Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801

Author

Muñoz Couselo, E., Berciano-Guerrero, M-Á., Manzano, J.L., Soria, A., Cerezuela-Fuentes, P., Crespo, G., Antoñanzas, M., Puértolas, T., García Castaño, A., Gutiérrez Sanz, L., Espinosa, E., Ayala de Miguel, P., Majem, M., López Castro, R., Fernández-Morales, L.A., Rivas, B., Medina, J., Berrocal, A., Martín Algarra, S., and Márquez-Rodas, I.

Published
2023
Full Text
View/download PDF

9. 1159P Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801

Author

Cerezuela-Fuentes, P., Piñero-Madrona, A., Muñoz-Couselo, E., Manzano, J.L., Berciano-Guerrero, M-Á., Majem, M., Espinosa, E., Soria, A., Ayala de Miguel, P., García Castaño, A., Crespo, G., Gutiérrez Sanz, L., Aguado de la Rosa, C., Fernández-Morales, L.A., Puértolas, T., Fra, J., Rodríguez de la Borbolla, M., Bellido, L., Martín Algarra, S., and Márquez-Rodas, I.

Published
2023
Full Text
View/download PDF

12. 1088P Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901 - DESCRIBE-AD)

Author

Manzano, J.L., Martín-Liberal, J., Fernandez-Morales, L.A., Benítez, G., Medina, J., Quindós, M., García-Castaño, A., Fernández, O., Vilchez Simo, R., Majem, M., Bellido Hernández, L., Ayala de Miguel, P., Campos, B., Espinosa, E., Macías Cerrolaza, J.A., Gil-Arnaiz, I., Lorente, D., Martínez-Fernández, A., Martín-Sánchez, E., and Cerezuela-Fuentes, P.

Published
2021
Full Text
View/download PDF

13. 1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study

Author

Marquez-Rodas, I., Berciano Guerrero, M.A., Muñoz Couselo, E., Manzano, J.L., Crespo Herrero, G., Soria, A., Cerezuela, P., Puertolas Hernandez, T., Berrocal, A., Majem Tarruella, M., Bellido Hernández, L., Espinosa, E., Garcia Castano, A., Medina Martínez, J., Fernandez Morales, L.A., Aguado de la Rosa, C., Gutierrez Sanz, L., Lopez Castro, R., Ayala de Miguel, P., and Martin Algarra, S.

Published
2021
Full Text
View/download PDF

14. Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer

Author

L. A. Fernández-Morales, M. A. Segui, C. Martinez Vila, P. Ribera, H. Oliveres, E. Dalmau, J. C. Pardo, and M. Marín

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Fulvestrant, business.industry, Hematology, medicine.disease, 03 medical and health sciences, Prostate cancer, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business, medicine.drug
Published
2017
Full Text
View/download PDF

16. 230P - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens

Author

Marin Alcala, M., Llort Pursals, G., Del Riego Ferrari, J.H., Giner, J., Andreu Navarro, F.X., Medina, S., Aparicio, O., Dalmau Portulas, E., Ribera Fernandez, P., Oliveres, H., Martinez Vila, C., Cabrera Romero, J.M., Segui Palmer, M.A., and Fernandez Morales, L.A.

Published
2018
Full Text
View/download PDF

17. Association Between Insulin Resistance (Ir) and Pathologic Complete Response (Pcr) to Neoadjuvant Chemotherapy (Nac) Among No Diabetic Women with Localized Infiltrating Breast Cancer (Libc)

Author

Armengol-Alonso, A., primary, Tusquets, I., additional, Servitja, S., additional, Fernández-Morales, L., additional, Segui-Palmer, M.A., additional, Campayo, M., additional, González-Farré, X., additional, Fernández, P.L., additional, Gascón, P., additional, and Muñoz, M., additional

Published
2014
Full Text
View/download PDF

18. Association Between Insulin Resistance (Ir) and Pathologic Complete Response (Pcr) to Neoadjuvant Chemotherapy (Nac) Among No Diabetic Women with Localized Infiltrating Breast Cancer (Libc)

Author

Pedro L. Fernández, Pere Gascón, L. Fernández-Morales, Montse Muñoz, M. Campayo, A. Armengol-Alonso, Ignasi Tusquets, M.A. Segui-Palmer, Sonia Servitja, and X. González-Farré

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Insulin, Hematology, medicine.disease, Basal (phylogenetics), Breast cancer, Insulin resistance, Internal medicine, Diabetes mellitus, medicine, Metabolic syndrome, Prospective cohort study, business, Neoadjuvant therapy
Abstract

Aim: The IR has been associated with increased risk of breast cancer (BC) and as a poor prognostic factor for relapse and survival. There is a lack of prospective studies that have reviewed the impact of IR across the NAC time and the likelihood of pCR. We determined the association between IR by HOMA2 (homeostasis model assessment) and pCR in LIBC. Methods: It was a prospective cohort, multicenter study. From 2012 to 2013, 64 patients were enrolled. Metabolic syndrome (MS) diagnosis was made by ATP III criteria. Insulin and glucose were measured at baseline and every 3 weeks during NAC. The IR was calculated by HOMA2 –IR.® Cut off value to define IR: HOMA2 ≥1.9. pCR (breast + nodes) was defined as no residual IBC. Results: Median age was 49 years. Axillary nodes were involved in 37 (57.8%). cTNM stage was II 50 (78.1%) and III 14 (21.8%). pCR (full cohort) was 37.5%. pCR in luminal A/B-like, triple negative and HER2 was 15.6%, 61.1% and 57.1% respectively. 25% had MS at baseline and up to 40% (final evaluation). At baseline 29 (45.3%) had IR and in final 34 (53.1%) (p = 0.005). We observed a gradual and almost linear increase of IR during the NAC time (p = 0.019). The group without IR (baseline) had a higher likelihood of pCR (HR 3.1, 95% CI 1.3-7.3). In the pCR group the HOMA2 remained below or slightly above 1.9 and with no changes over time (p = 0.225). Inversely in the no pCR group the IR increased over time and almost with a linear trend (p = 0.013). In a repeated measures analysis of HOMA2 over NAC time in the three biological subgroups, differences were observed only in luminal-like (p = 0.044). Comparing quartiles (Q1-2 vs Q3-4), basal insulin (p =0.018) and basal HOMA2 (p = 0.032) were significantly associated with pCR. In an adjusted logistic regression analysis for pCR, the IR remained as an independent factor for pCR (p = 0.018). Conclusions: We found a strong association between the status of IR and the likelihood of pCR in neoadjuvant setting of BC. To our knowledge this is the first prospective study describing the natural history of IR across time of the NAC. The IR increased over time of the NAC and the pCR likelihood is inversely associated with IR. Our findings suggest that the increase in central adiposity during NAC time produces a greater insulin resistance and thereby a cell proliferative environment resulting in a lower response to NAC. Disclosure: All authors have declared no conflicts of interest.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results